Non-Small Cell Lung Cancer (NSCLC)

Sintilimab with gemcitabine plus platinum produced superior clinical benefit for patients with locally advanced or metastatic squamous cell non–small cell lung cancer when compared with gemcitabine plus platinum alone.

At ASCO 2021, Stephen Liu, MD, discussed his excitement for results of the IMpower010 trial of atezolizumab in patients with early-stage resected non–small cell lung cancer

Foundation Medicine announced the expanded indication for FoundationOne Liquid CDx as a companion diagnostic to identify MET exon 14 skipping mutations in metastatic non–small cell lung cancer.

At ASCO 2021, Stephen Liu, MD, talked about treating patients with EGFR-mutant non–small cell lung cancer in the post-osimertinib setting with the combination of amivantamab and Lazertinib.

Patients with KRAS-positive NSCLC being treated with rigosertib plus nivolumab demonstrated early efficacy of the combination in a phase 1/2a trial.

FoundationOne CDx, a comprehensive genomic profiling test, has been approved for use in conjunction with brigatinib to test for solid tumors in patients with ALK-positive NSCLC.

Phase 2 data showed just over half of patients given dual therapy had a major pathological response, compared to just 6.7% of those receiving durvalumab monotherapy.

CancerNetwork® sat down with Salma Jabbour, MD, of Rutgers Cancer Institute, at 2021 ASCO to talk about what she believed was the most interesting and impactful study to come out of the meeting.

Joshua Sabari, MD, discussed the approval of amivantiamab as therapy for patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Based on positive single-agent activity in patients with non–small cell lung cancer harboring a KRAS G12C mutation, adagrasib wins FDA breakthrough therapy designation.

At the 2021 ASCO Annual Meeting, Stephen Liu, MD, discussed the important of findings from the ARROW trial of pralsetinib in patients with RET-altered non–small cell lung cancer.

During the 2021 ASCO Annual Meeting, Suresh S. Ramalingam, MD, looked forward to how trials regarding adjuvant therapy for early-stage non–small cell lung cancer are poised to change the treatment paradigm in this setting.

McCall and Higgins examine local ablative therapy for oligometastatic NSCLC and implications for future treatment of the disease.

Patients who had resection within 12 weeks of diagnosis of stage I NSCLC were found to have lower rates of recurrence.

Bemcentinib plus PD-1/L1 inhibition moves forward as therapy for patients with AXL-expressing non–small cell lung cancer.

Jabbour detailed the importance of managing care in a multidisciplinary setting for patients enrolled in the KEYNOTE-799 trial with stage III NSCLC.

Among other things, Pennell focused on data regarding atezolizumab as adjuvant therapy to improve disease-free survival for patients with stage II/III resected non–small cell lung cancer.

According to data presented at the 2021 ASCO Annual Meeting, patients with crizotinib-refractory ALK-positive non–small cell lung cancer demonstrated long-term response and survival maintenance on brigatinib.

Reck mentioned the IMpower010 and CheckMate 816 trials investigating treatment options for patients with non-small cell lung cancer.

Larotrectinib’s tumor-agnostic indication for NTRK fusion–positive cancers is further validated by data presented at the 2021 ASCO Annual Meeting.

Patients with platinum-pretreated EGFR exon 20 insertion mutation–positive metastatic non–small cell lung cancer experienced antitumor activity with oral TKI mobocertinib, according to results presented at the 2021 ASCO Annual Meeting.

Compared with immediate prior therapy, selpercatinib resulted in a greater proportion of objective responses in patients with non–small cell lung cancer whose tumors harbor RET fusions.

Patients with pretreated KRAS p.G12C–mutated NSCLC experienced a continued durable clinical benefit with sotorasib.

For heavily pretreated patients with EGFR-mutated NSCLC resistant to EGFR TKIs, patritumab deruxtecan induced clinically meaningful and durable efficacy.

Some patients who progressed on osimertinib had a response to therapy with amivantamab and lazertinib, and these were seen regardless of known resistance mechanisms to EGFR inhibitors.